fda glp-1 news november 2025 weight loss drugs are back in the GLP-1 Shortage = Over -

JAMA Ophthalmol 2023;141:8:747-754

For diabetes management , the most important metric is blood glucose control

The current federal multidistrict litigation alleges that some patients developed severe digestive complications involving delayed gastric emptying, persistent vomiting, dehydration, malnutrition, abdominal pain, or intestinal blockage after taking GLP-1 medications

Importantly, the improved menstrual regularity seen in women with PCOS on semaglutide, where 80 percent of responsive patients normalized their cycles, suggests that the medication can be profoundly positive for reproductive and sexual health in the right population